IHM
Iguana Healthcare Management Portfolio holdings
AUM
$133M
This Quarter Return
+7.86%
1 Year Return
+45.66%
3 Year Return
+127.07%
5 Year Return
–
10 Year Return
–
AUM
$133M
AUM Growth
+$133M
(-12%)
Cap. Flow
-$18M
Cap. Flow
% of AUM
-13.5%
Top 10 Holdings %
Top 10 Hldgs %
36.02%
Holding
84
New
22
Increased
15
Reduced
14
Closed
22
Top Buys
| 1 |
SHPG
Shire pic
SHPG
|
$3.74M |
| 2 |
Centene
CNC
|
$3.21M |
| 3 |
ALXN
Alexion Pharmaceuticals Inc
ALXN
|
$3.07M |
| 4 |
Labcorp
LH
|
$2.83M |
| 5 |
DexCom
DXCM
|
$2.6M |
Top Sells
| 1 |
CELG
Celgene Corp
CELG
|
$7.83M |
| 2 |
AERI
Aerie Pharmaceuticals, Inc.
AERI
|
$5.08M |
| 3 |
AbbVie
ABBV
|
$4.84M |
| 4 |
Esperion Therapeutics
ESPR
|
$4.7M |
| 5 |
KTWO
K2M Group Holdings, Inc
KTWO
|
$2.84M |
Sector Composition
| 1 | Healthcare | 89.09% |
| 2 | Energy | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Esperion Therapeutics
ESPR
$448M
| $7.23M | 4.76% |
100,000
-65,000
| -39% | -$4.7M |
|
|
IMMU
2
DELISTED
Immunomedics Inc
IMMU
| $5.84M | 3.84% |
400,000
-50,000
| -11% | -$731K |
|
|
GBT
3
DELISTED
Global Blood Therapeutics, Inc.
GBT
| $5.56M | 3.65% |
115,000
-10,000
| -8% | -$483K |
|
4
Humana
HUM
$36.5B
| $5.38M | 3.54% |
20,000
-2,500
| -11% | -$672K |
|
5
Biogen
BIIB
$19.4B
| $4.79M | 3.15% |
17,500
-4,500
| -20% | -$1.23M |
|
6
Merck
MRK
$210B
| $4.36M | 2.87% |
80,000
| – | – |
|
|
ARNA
7
DELISTED
Arena Pharmaceuticals Inc
ARNA
| $3.95M | 2.6% |
100,000
+50,000
| +100% | +$1.98M |
|
|
SHPG
8
DELISTED
Shire pic
SHPG
| $3.74M | 2.46% |
+25,000
| New | +$3.74M |
|
|
CLVS
9
DELISTED
Clovis Oncology, Inc.
CLVS
| $3.7M | 2.43% |
70,000
+10,000
| +17% | +$528K |
|
10
AnaptysBio
ANAB
$569M
| $3.38M | 2.23% |
32,500
-7,500
| -19% | -$781K |
|
11
Cigna
CI
$80.3B
| $3.36M | 2.21% |
20,000
-5,000
| -20% | -$839K |
|
12
Viatris
VTRS
$12.3B
| $3.29M | 2.17% |
80,000
+40,000
| +100% | +$1.65M |
|
|
13
Centene
CNC
$14.3B
| $3.21M | 2.11% |
+30,000
| New | +$3.21M |
|
14
Bristol-Myers Squibb
BMY
$96B
| $3.16M | 2.08% |
50,000
| – | – |
|
|
ALXN
15
DELISTED
Alexion Pharmaceuticals Inc
ALXN
| $3.07M | 2.02% |
+27,500
| New | +$3.07M |
|
16
Ultragenyx Pharmaceutical
RARE
$2.89B
| $3.06M | 2.01% |
60,000
+10,000
| +20% | +$510K |
|
17
Abbott
ABT
$231B
| $3M | 1.97% |
50,000
-25,000
| -33% | -$1.5M |
|
|
18
Labcorp
LH
$23.1B
| $2.83M | 1.86% |
+17,500
| New | +$2.83M |
|
19
ADMA Biologics
ADMA
$4.12B
| $2.76M | 1.82% |
600,000
| – | – |
|
|
20
DexCom
DXCM
$29.5B
| $2.6M | 1.71% |
+35,000
| New | +$2.6M |
|
21
Gyre Therapeutics
GYRE
$703M
| $2.58M | 1.7% |
+100,000
| New | +$2.58M |
|
|
TSRO
22
DELISTED
TESARO, Inc.
TSRO
| $2.57M | 1.69% |
45,000
+10,000
| +29% | +$571K |
|
|
ZSAN
23
DELISTED
Zosano Pharma Corporation
ZSAN
| $2.52M | 1.66% |
+500,000
| New | +$2.52M |
|
24
Sangamo Therapeutics
SGMO
$157M
| $2.38M | 1.56% |
125,000
-25,000
| -17% | -$475K |
|
25
GSK
GSK
$79.9B
| $2.34M | 1.54% |
60,000
+30,000
| +100% | +$1.17M |
|